Health Care Analysis, Division of Society and Health, Linköping University, Linköping, Sweden.
The NEPI Foundation, Stockholm, Sweden.
Basic Clin Pharmacol Toxicol. 2023 Feb;132(2):171-179. doi: 10.1111/bcpt.13816. Epub 2022 Dec 5.
A framework for analysing incidence in pharmacoepidemiology and drug statistics is suggested using statins as an example. A new case of statin use (first-ever use or recurrence of treatment) can be defined as new on the group (NoG), new on substance whether new on the group or not (NoS), new on substance and new on the group (NoS_and_NoG), new on substance and not new on the group (NoS_not_NoG).
Individual-level dispensations of statins 2006-2019 for 1 017 058 individuals with at least one dispensation 2019 in Sweden.
With 12-month run-in, corresponding to at least 8 months without treatment, the incidence proportion of NoG was 13.39 new cases per 1000 inhabitants and 8.40 with 10-year run-in. Thus, 37% had first been treated with any statin between 12 months and 10 years before the index date. For atorvastatin, NoS was 10.69, NoS_and_NoG 9.99, and NoS_not_NoG 0.70 per 1000 inhabitants. 0.70 per 1000 inhabitants or 6.6% of new cases of atorvastatin represented a change from another statin during the run-in.
It is essential to separate new cases that are new both on the substance and on the group from those that represent a change of therapy during the run-in.
本文提出了一种用于分析药物流行病学和药物统计数据的方法，以他汀类药物为例。新的他汀类药物使用（首次使用或再次治疗）可以定义为组内新病例（NoG）、无论是否为组内新病例，药物新病例（NoS）、药物和组内新病例（NoS_and_NoG）、药物新但组内无新病例（NoS_not_NoG）。
以瑞典 2006 年至 2019 年至少有一次 2019 年处方的 1017058 名个体的他汀类药物个人配药为基础。
采用 12 个月洗脱期（至少 8 个月无治疗），NoG 的发病率比例为每 1000 名居民中有 13.39 例新病例，10 年洗脱期为 8.40 例。因此，37%的患者在索引日期前 12-10 年内首次接受任何他汀类药物治疗。阿托伐他汀的 NoS 为 10.69，NoS_and_NoG 为 9.99，NoS_not_NoG 为 0.70/1000 居民。阿托伐他汀新病例的 0.70/1000 居民或 6.6%代表洗脱期内从另一种他汀类药物的转换。
从组内和药物内的新病例中分离出代表洗脱期内治疗变化的新病例是至关重要的。
